Market Overview

According to fortune business insights, The global hemato oncology testing market size was valued at USD 4.54 billion in 2025. The market is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, exhibiting a CAGR of 7.2% during the forecast period. North America dominated the global hemato oncology testing market with a market share of 40.96% in 2025.

The analysis shows that market growth is attributed to the rising adoption of advanced tests for the detection of blood cancers such as leukemia, lymphoma, and myeloma. The introduction of easier-to-run tests, the rising prevalence of blood disorders, and a growing emphasis on preventive care are also driving market growth. Key industry players are focusing on introducing technologically advanced products to meet this demand.

Major Players Profiled in the Market Report:

• Hoffmann-La Roche AG (Switzerland)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Sysmex Corporation (Japan)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• BD (U.S.)
• Invivoscribe, Inc. (U.S.)
• Invitae Corporation (U.S.)

Segments

Significant Adoption of Assay Reagents and Kits to Accelerate Segmental Growth
Based on products & services, the market is divided into assay kits & reagents, services, and instruments & platforms. The assay kits & reagents segment holds the largest share due to repetitive purchases driven by high test volumes and growing awareness.

Higher Prevalence to Drive Lymphoma Segment Growth
By cancer type, the market is segmented into leukemia, lymphoma, multiple myeloma, and others. The lymphoma segment dominated the market as its many subtypes require accurate classification to guide treatment decisions.

Technological Advancements to Drive Molecular Diagnostics Segment
Based on testing technology, the market is categorized into molecular diagnostics, flow cytometry, and others. The molecular diagnostics segment dominated due to its ability to provide specific disease information that supports therapy decisions and monitoring.

Higher Testing Volumes in Hospitals & Diagnostic Centers to Accelerate Segment Growth
By end-user, the market is segmented into hospitals & diagnostic laboratories, academic & research institutes, and others. The hospitals & diagnostic laboratories segment holds the largest share as it is the primary point where patients are tested and treatment decisions are made.

Source: https://www.fortunebusinessinsights.com/hemato-oncology-testing-market-115278

Drivers & Restraints

Growing Demand for Personalized Cancer Treatment to Boost Market Growth
The market is witnessing a rising demand for personalized therapeutics. Healthcare professionals are focusing on personalized test results to provide accurate, targeted therapies, which creates a steady demand for tests that can confirm cancer types and detect key disease signals.

However, the high cost of testing products and services, coupled with irregular reimbursement policies, can hamper market growth. These factors can limit test volumes, as some hospitals may restrict advanced testing and smaller labs may avoid adding new tests due to budget constraints.

Hemato Oncology Testing Market Future Growth:

A prominent trend in the market is the rising adoption of molecular diagnostics for screening blood cancer. The benefits offered by molecular diagnostics, such as higher accuracy, product availability, and shorter turnaround times, are supporting this shift. Market players are contributing to this trend by launching new and more accessible panels and assays for clinical labs.

Competitive Landscape

Focus on Introduction of New Products by Key Players to Propel Market Progress
The global market has a semi-consolidated structure, with key players such as F. Hoffmann-La Roche AG, Abbott, and Danaher Corporation holding a significant share. These companies engage in strategic activities, such as collaborations, and focus on introducing new products with advanced technologies. Other prominent players also prioritize new product launches to increase their global market share.

Key Industry Developments

• October 2025: Flatiron Health announced the launch of its new AI-powered hematology datasets to accelerate clinical trials and treatment outcome assessment.
• May 2025: Labcorp announced an expansion of its oncology portfolio to boost advanced research and cancer care.